Tolerability, Pharmacokinetics, and Neuroendocrine Effects of PRX‐00023, a Novel 5‐HT1A Agonist, in Healthy Subjects

  title={Tolerability, Pharmacokinetics, and Neuroendocrine Effects of PRX‐00023, a Novel 5‐HT1A Agonist, in Healthy Subjects},
  author={Ganesh R. Iyer and John F. Reinhard Jr and Scott Oshana and Michael G. Kauffman and Stephen Donahue},
  journal={The Journal of Clinical Pharmacology},
PRX‐00023 is a novel, nonazapirone 5‐HT1A agonist in clinical development for treatment of affective disorders. The objectives of the initial clinical phase I studies (a single ascending dose study and multiple dose‐ascending and high‐dose titration studies) were to measure the pharmacokinetics, pharmacodynamic (neuroendocrine) effects, and tolerability of PRX‐00023 in healthy subjects. The studies evaluated 10‐mg to 150‐mg doses of PRX‐00023 in up to 112 healthy male and female subjects aged… 

Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled Trial

The anxiolytic effect of PRX-00023, compared with placebo, showed trends across all anxIOlytic measures but failed to reach significance on the primary endpoint (HAM-A total score).

A Novel Study Using Accelerated Mass Spectrometry to Evaluate the Pharmacokinetics of Total 14C AL‐8309 (Tandospirone) Following Topical Ocular Administration in Healthy Male Subjects

Single and multiple topical doses of AL‐8309B were found to be safe and well‐tolerated in healthy subjects and this is the first reported use of accelerator mass spectrometry technology with a topically applied ophthalmic product.

Current and emerging drug therapies for the treatment of depression in adults with epilepsy

Though promising, the level of evidence provided by these studies is still low as the majority have relevant methodological limitations, and SSRIs are the drug class with the largest amount of data.

A resurging boom in new drugs for epilepsy and brain disorders

This article reviews in detail top new drugs that are currently in clinical trials or agents that are under development and have novel mechanisms of action for epilepsy and seizure disorders.

Rational drug design approach of the myeloperoxidase inhibition: From in silico to pharmacological activity

This cumulative work including X-ray data, the role of MPO in different pathologies, MPO inhibitory mechanism of action, screening and various chemical entities that inhibit MPO, provided sufficient elements to start a new drug design and drug discovery process on MPO.



Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses

In view of high intra-and inter-subject variability in buspirone concentrations, definitive dosing recommendations for patients with compromised renal or hepatic function could not be made, but such patients should initially be dosed cautiously with buspir one.

Metabolism and disposition of buspirone.

1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat.

Results, together with the fact that PmP is biochemically and pharmacologically active, suggest that the metabolite may contribute significantly to the central effects of the parent drug.

The pharmacology of putative early-onset antidepressant strategies

  • P. Blier
  • Psychology, Biology
    European Neuropsychopharmacology
  • 2003

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.

We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of anxiety and depression, which is now in Phase III clinical trials for

Anxiolytics: past, present, and future agents.

  • C. Nemeroff
  • Psychology
    The Journal of clinical psychiatry
  • 2003
The long-sought-after class of anxiolytics that are both effective and safe may be found in the new research being conducted with agents that selectively target GABA receptors and their subtypes.

Williams Textbook of endocrinology

Williams textbook of endocrinology / , Williams textbook of endocrinology / , کتابخانه دیجیتال جندی شاپور اهواز

Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug

The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors.